Comparative Pharmacology
Head-to-head clinical analysis: KADCYLA versus MARGENZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KADCYLA versus MARGENZA.
KADCYLA vs MARGENZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Margetuximab is an Fc-engineered monoclonal antibody that targets the extracellular domain of human epidermal growth factor receptor 2 (HER2). It binds to HER2 on tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) via enhanced affinity for activating Fcγ receptors (FcγRIIIa) and reduced affinity for inhibitory FcγRIIb, thereby augmenting immune effector cell activation.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
15 mg/kg intravenously over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal half-life approximately 17-23 days (mean ~20 days) following intravenous administration, supporting a 3-week dosing interval for sustained receptor occupancy.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Primarily cleared via proteolytic degradation; renal excretion of intact drug is negligible (<1%). No significant biliary or fecal elimination reported.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent